BIODESIX INC (BDSX) Form 8-K — May 4, 2026
Biodesix, Inc. reported strong first quarter 2026 financial results, with total revenue growing 42% year-over-year to $25.6 million. This growth was driven by a 37% increase in Diagnostic Testing revenue to $22.3 million and a 99% increase in Development Services revenue to $3.3 million. The company achieved a gross margin of 84% and reduced its net loss by 30% compared to the prior year period.
Key figures
- Revenue
- 25555000
- Guidance
- Total revenue of $108-114 million for full year 2026
- Revenue Yoy
- 42%
- Cash Position
- 25572000
- Gross Margin Percent
- 84
- Diagnostic Testing Revenue
- 22291000
- Development Services Revenue
- 3264000
Price after filing
1 day: +32.6%7 days: +42.9%30 days: +42.9%
Close on the filing date to close N calendar days later (from $11.27). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.